Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kipps, Thomas J. [1 ]
Wierda, William G. [2 ]
Jones, Jeffrey A. [3 ]
Swinnen, Lode J. [4 ]
Yang, Jianning [5 ]
Cui, Yue [5 ]
Busman, Todd [5 ]
Krivoshik, Andrew [5 ]
Enschede, Sari [5 ]
Humerickhouse, Rod [5 ]
机构：
[1] Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1019 / 1019
页数：1
相关论文
共 50 条
  • [1] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    [J]. BLOOD, 2011, 118 (21) : 1669 - 1669
  • [2] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    [J]. HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [3] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [4] Improved survival in patients with relapsed - Refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination.
    Wierda, W
    O'Brien, S
    Faderl, S
    Ferrajoli, A
    Lerner, S
    Wang, XM
    Thomas, D
    Garcia-Manero, G
    Cortes, J
    Kantarjian, H
    Keating, M
    [J]. BLOOD, 2003, 102 (11) : 110A - 110A
  • [5] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
    Grifi, Fatiha
    Bougherira, Soraya
    Djenouni, Amel
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94
  • [6] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [7] Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
    Byrd, John C.
    Kipps, Thomas J.
    Flinn, Ian W.
    Castro, Januaro
    Lin, Thomas S.
    Wierda, William
    Heerema, Nyla
    Woodworth, James
    Hughes, Steve
    Tangri, Shabnam
    Harris, Sarah
    Wynne, Dee
    Molina, Arturo
    Leigh, Bryan
    O'Brien, Susan
    [J]. BLOOD, 2010, 115 (03) : 489 - 495
  • [8] PENTOSTATIN, CYCLOPHOSPHAMIDE AND RITUXIMAB (PCR) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Mannina, D.
    Chiarenza, A.
    Di Raimondo, F.
    Musso, M.
    Bonanno, V.
    Nocilli, L.
    Sciarrone, A.
    Brugiatelli, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 589 - 589
  • [9] Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)
    Al-Sawaf, Othman
    Robrecht, Sandra
    Bahlo, Jasmin
    Fink, Anna Maria
    Cramer, Paula
    Maurer, Christian
    Bergmann, Manuela A.
    Dreyling, Martin H.
    Lange, Elisabeth
    Kneba, Michael
    Stilgenbauer, Stephan
    Dohner, Hartmut
    Kiehl, Michael G.
    Jager, Ulrich
    Wendtner, Clemens-Martin
    Fischer, Kirsten
    Hallek, Michael
    Eichhorst, Barbara F.
    Hopfinger, Georg
    [J]. BLOOD, 2016, 128 (22)
  • [10] The treatment of complicated and high risk chronic lymphocytic leukemia (CLL) with fludarabine, cyclophosphamide and rituximab (FCR).
    Donthireddy, V
    Shurafa, MS
    Saleh, M
    Kamboj, G
    Wang, D
    Janakiraman, N
    [J]. BLOOD, 2005, 106 (11) : 341B - 341B
12345